MTHFR Gene: What Your Variant Actually Means (No Hype, Just Science)

Few genetic variants have generated as much internet noise as MTHFR. Search for it and you will find claims that MTHFR mutations cause everything from depression and infertility to cancer and autism. Entire supplement empires have been built on the back of this single gene.

The reality is far more measured. MTHFR variants are extremely common, most carriers are perfectly healthy, and the scientific evidence supports concern in only a handful of specific clinical scenarios. This article breaks down what the MTHFR gene actually does, what the two main variants mean, and when -- if ever -- you should care about your result.

What the MTHFR Gene Actually Does

MTHFR stands for methylenetetrahydrofolate reductase. It is not an acronym you need to memorize. What matters is the job the enzyme performs.

Your body needs folate (vitamin B9) for a range of critical processes: building DNA, repairing cells, and regulating gene expression through a chemical process called methylation. But dietary folate cannot do these jobs directly. It has to be converted through a series of biochemical steps known as the folate cycle.

The MTHFR enzyme handles one specific step in this cycle: it converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-methylTHF). This product, 5-methylTHF, is the primary circulating form of folate in your blood and the form your body actually uses to donate methyl groups.

Those methyl groups are essential. They feed into the methionine cycle, where they help convert homocysteine (an amino acid) back into methionine. Methionine then becomes S-adenosylmethionine (SAMe), the universal methyl donor your body uses for hundreds of reactions, including DNA methylation, neurotransmitter synthesis, and detoxification.

So in short: MTHFR helps your body use folate effectively. When the enzyme works less efficiently, less 5-methylTHF is produced, which can lead to elevated homocysteine levels -- but only under certain conditions.

The Two Main Variants: C677T and A1298C

Two single-nucleotide polymorphisms (SNPs) in the MTHFR gene have been studied extensively.

C677T (rs1801133)

This is the more clinically significant variant. The "T" allele results in an amino acid change (alanine to valine) at position 222 of the enzyme, producing a thermolabile version that is less stable at body temperature.

• Heterozygous (CT): One copy of the T allele. Enzyme activity is reduced to roughly 65% of normal. This is very common.
• Homozygous (TT): Two copies. Enzyme activity drops to about 30% of normal. This is where measurable biochemical effects become more likely.

The CT genotype is found in approximately 40% of people of European descent. The TT genotype occurs in roughly 8-12% of Europeans, with higher frequencies in certain populations (up to 20-25% in parts of Southern Europe and Latin America). In East Asian populations, TT prevalence is around 10-12%. In populations of African descent, TT is less common (1-2%).

These are not rare mutations. They are common polymorphisms that have persisted in human populations for thousands of years.

A1298C (rs1801131)

This variant causes a glutamate-to-alanine substitution at position 429. Its effect on enzyme activity is milder than C677T.

• Heterozygous (AC): Minimal impact on enzyme function.
• Homozygous (CC): Enzyme activity reduced to approximately 60% of normal.

A1298C on its own is generally not considered clinically significant. The compound heterozygous state (one copy of C677T and one copy of A1298C) has been studied, with some evidence of moderately reduced enzyme activity, but the clinical relevance remains debated.

What the Evidence Actually Says

Here is where we need to separate signal from noise. The peer-reviewed literature supports clinical relevance for MTHFR variants in a limited number of scenarios.

Where MTHFR Variants Genuinely Matter

Neural tube defects and pregnancy. This is the most well-established association. Women who are homozygous TT for C677T have a moderately increased risk of having a child with a neural tube defect (NTD), particularly when folate intake is low. A meta-analysis published in the American Journal of Epidemiology (Botto & Yang, 2000) found that maternal TT genotype was associated with roughly a twofold increase in NTD risk. This is one of the key reasons folic acid fortification of grain products was introduced in many countries -- and it worked. NTD rates dropped significantly after fortification programs began.

Elevated homocysteine. The TT genotype is consistently associated with higher plasma homocysteine levels, particularly when folate status is low (Frosst et al., 1995, Nature Genetics). Elevated homocysteine is an independent risk factor for cardiovascular disease, though the relationship is more nuanced than once thought. Large randomized trials of homocysteine-lowering with B vitamins (HOPE-2, VITATOPS) showed modest reductions in stroke risk but no significant effect on heart attacks or overall mortality. The current consensus: elevated homocysteine is a marker worth monitoring, but MTHFR genotype alone is not a reliable predictor of cardiovascular events.

Methotrexate response. Methotrexate is a folate antagonist used to treat rheumatoid arthritis, certain cancers, and autoimmune conditions. Because MTHFR variants affect folate metabolism, they can influence how patients respond to methotrexate and their risk of side effects. Several studies have found that TT homozygotes are more likely to experience methotrexate toxicity (Weisman et al., 2006). If you are being prescribed methotrexate, knowing your MTHFR status may be clinically useful. For a broader look at how genetics influence medication response, see our pharmacogenomics guide.

Where MTHFR Variants Probably Do Not Matter

Depression and anxiety. While some early studies suggested an association between C677T TT and depression, larger and better-designed studies have failed to confirm a meaningful link. A 2017 meta-analysis in Journal of Affective Disorders (Gilbody et al.) found that the association was weak and heavily confounded. MTHFR status is not a useful predictor of depression risk.

Autism. Several meta-analyses have examined the MTHFR-autism link. While some show a marginal statistical association, the effect sizes are tiny and the studies are plagued by publication bias and heterogeneity. No major clinical guideline recommends MTHFR testing in the context of autism.

Chronic fatigue, fibromyalgia, and "detox" issues. There is no credible evidence that MTHFR variants cause chronic fatigue syndrome, fibromyalgia, or impaired detoxification. These claims are pervasive in wellness communities but are not supported by controlled studies.

Cancer. The relationship between MTHFR and cancer risk has been studied extensively with mixed results. Some cancers show a slightly reduced risk in TT carriers (possibly due to altered nucleotide balance favoring DNA stability), while others show a slight increase. The effects are small and inconsistent across populations. MTHFR genotype is not used in any standard cancer screening or risk assessment protocol.

The Methylation Myth Industry

Let us be direct: a significant wellness industry has grown around MTHFR, and much of it is not grounded in evidence.

The typical narrative goes something like this: "You have an MTHFR mutation, so your methylation is broken. This is causing your fatigue, brain fog, anxiety, and hormonal issues. You need methylfolate, methylcobalamin, SAMe, and a dozen other supplements to fix your methylation."

This framing has several problems.

First, having a common variant is not the same as having a "broken" gene. The C677T T allele is carried by roughly half the global population. If this variant truly caused the cascade of symptoms attributed to it, we would expect to see clear, large-scale epidemiological signals. We do not.

Second, methylation is not a single on/off switch. It is a vast network of biochemical reactions influenced by hundreds of genes, dietary factors, and environmental inputs. Reducing it to one SNP in one gene is a dramatic oversimplification.

Third, the supplement recommendations are often untested. While methylfolate (5-methylTHF) is a legitimate and bioavailable form of folate, the elaborate supplement stacks marketed to "MTHFR mutants" have not been validated in clinical trials. Some of these products are expensive and unnecessary for the vast majority of carriers.

The American College of Medical Genetics (ACMG) issued a practice guideline in 2013 stating that MTHFR testing should not be ordered as part of a clinical evaluation for thrombophilia or recurrent pregnancy loss, because the results rarely change clinical management.

Practical Advice: What Should You Actually Do?

If you have learned that you carry one or two copies of the C677T or A1298C variant -- perhaps through a consumer genetics test -- here is what the evidence supports.

Folate Intake Matters More Than Your Genotype

Whether or not you carry an MTHFR variant, adequate folate intake is important for everyone. The recommended daily intake for adults is 400 micrograms of dietary folate equivalents (DFE), increasing to 600 mcg during pregnancy.

Good dietary sources of folate include:

• Dark leafy greens: spinach, kale, collard greens, romaine lettuce
• Legumes: lentils, chickpeas, black beans, kidney beans
• Asparagus and broccoli
• Citrus fruits and avocado
• Fortified grains (in countries with mandatory fortification)

Methylfolate vs. Folic Acid

Folic acid is the synthetic form of folate used in supplements and food fortification. It must be converted through multiple enzymatic steps -- including the MTHFR step -- to become active 5-methylTHF.

Methylfolate (also called L-5-MTHF or L-methylfolate) is the already-converted, bioactive form. It bypasses the MTHFR enzyme entirely.

For people with TT genotype who want additional reassurance, choosing a supplement that contains methylfolate rather than folic acid is a reasonable and evidence-supported choice. However, it is worth noting that even TT homozygotes can convert folic acid -- just less efficiently. Folic acid supplementation has been shown to lower homocysteine levels even in TT carriers when given at adequate doses (Ashfield-Watt et al., 2002, American Journal of Clinical Nutrition).

There is no need to avoid folic acid entirely. But if you prefer or your clinician recommends it, methylfolate is a well-tolerated alternative.

B12 and B6

Vitamins B12 and B6 are also involved in homocysteine metabolism. Ensuring adequate intake of all three B vitamins (folate, B12, B6) is more important than obsessing over a single gene variant.

When to Talk to Your Doctor

MTHFR testing is not recommended as a routine screening test. However, consider discussing your MTHFR status with your healthcare provider if:

• You are planning a pregnancy and want to optimize your folate strategy, particularly if you have a personal or family history of neural tube defects.
• You have persistently elevated homocysteine levels that are not explained by other factors (B12 deficiency, kidney disease, hypothyroidism).
• You are being prescribed methotrexate or another folate-antagonist medication.
• You have a history of recurrent pregnancy loss, though current guidelines note that MTHFR testing alone is unlikely to change management.

For most other scenarios, knowing your MTHFR status is informative but not actionable in a way that requires medical intervention.

If you have raw data from a consumer genetics service and want to explore your results, our guide to using raw genetic data walks through how to access and interpret your files. And if you are considering which testing service to use, we have compared the best options available in Europe in 2026.

How DeepDNA Explains Your MTHFR Status

One of the challenges with genetic results is that they are often presented as raw genotypes -- "rs1801133: CT" -- without context about what the letters mean or whether you should care.

DeepDNA takes a different approach. When you upload your raw genetic data, our AI-powered analysis identifies your MTHFR variants and explains them in plain language: what your specific genotype means for enzyme function, how common it is in your ancestral population, and what -- if anything -- the evidence suggests you should consider.

We do not tell you your methylation is "broken." We do not sell you a supplement stack. We give you a clear, referenced summary that you can bring to your doctor or simply use to satisfy your own curiosity.

Because understanding your genetics should not require a biochemistry degree -- but it should be honest.

Key Takeaways

• MTHFR is one of the most common genetic variants in the world. Carrying it does not mean something is wrong with you.
• The enzyme converts folate into its active form. Reduced activity can lead to higher homocysteine, but usually only when folate intake is low.
• Clinical relevance is limited to pregnancy planning (neural tube defect risk), methotrexate treatment, and persistent hyperhomocysteinemia.
• The wellness industry has dramatically overstated the impact of MTHFR variants. Most claims about MTHFR causing chronic disease are not supported by rigorous evidence.
• Adequate folate intake from diet or supplements (methylfolate or folic acid) is the most practical step, regardless of genotype.
• Talk to your doctor if you are pregnant or planning to become pregnant, taking methotrexate, or have confirmed elevated homocysteine.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making decisions based on genetic test results.